Enlivex Therapeutics (NASDAQ:ENLV) Trading 2.4% Higher – Here’s What Happened

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) shares were up 2.4% during mid-day trading on Thursday . The company traded as high as $1.61 and last traded at $1.52. Approximately 255,775 shares were traded during mid-day trading, an increase of 154% from the average daily volume of 100,601 shares. The stock had previously closed at $1.49.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ENLV shares. EF Hutton Acquisition Co. I raised shares of Enlivex Therapeutics to a “strong-buy” rating in a report on Tuesday, August 27th. HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of Enlivex Therapeutics in a research report on Friday, September 27th.

Enlivex Therapeutics Stock Performance

The stock has a 50-day moving average of $1.43 and a 200 day moving average of $1.47. The firm has a market capitalization of $32.54 million, a P/E ratio of -1.29 and a beta of 1.04.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.06. On average, equities analysts predict that Enlivex Therapeutics Ltd. will post -0.7 EPS for the current year.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new position in Enlivex Therapeutics in the 2nd quarter valued at $35,000. Armistice Capital LLC bought a new position in Enlivex Therapeutics in the second quarter valued at about $2,415,000. Finally, Sigma Investment Counselors Inc. acquired a new position in Enlivex Therapeutics during the 3rd quarter valued at about $50,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.